This company’s product’s announcement with claims of its safety and effectiveness in promoting health in shrimp populations:

https://www.prnewswire.com/news-releases/viaqua-therapeutics-announces-8-25m-investment-led-by-s2g-ventures-to-scale-rna-based-solutions-in-aquaculture-301917390.html
ViAqua Therapeutics Announces $8.25M Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture

HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ — ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced [investment details]…

… ViAqua has developed a biotechnology-based oral delivery platform for the targeted administration of RNA-based solutions to improve disease resistance in aquaculture. …

…The company’s first product is a feed supplement to enhance resistance to viral infections in shrimp, with the initial application targeting White Spot Virus (WSSV) …

ViAqua Therapeutics website:
https://www.viaqua-t.com/solution

Our Solution:

…ViAqua is developing a biotechnology-based oral delivery platform for targeted administration of RNA-based solutions….

…The company’s first product is feed supplement for the improved resistance to viral diseases in shrimp, with the initial application against the widespread White Spot Shrimp Virus (WSSV).

…RNAi is a non-GMO, hormone-free supplement that is safe for shrimp and humans. It is a non-antibiotic, feed-grade material. …

Challenges of Oral Delivery
ViAqua successfully solved (and has overcome) a number of challenges to develop a viable orally administered formulation for the improved prevention of diseases in shrimp. The ViAqua platform —
1. provides protection of the RNA in the aquatic environment,
2. withstands barriers in the digestive system to ensure effective delivery of the RNA, and
3. integrates the coated particles for delivery via feed to achieve the maximum effect and to reduce costs.

Achievements: Additional Milestones
Developed particle formulation that protects the RNA in the challenging aquatic environment
Produced particles that can withstand, and pass through, barriers in the digestive system to deliver the RNA
Developed know-how and IP for particle administration to shrimp feed
Conducted several challenge tests at leading certified laboratory, demonstrating significant improvement in survival rate against the lethal WSSV in shrimp (resistance to additional viruses is being tested)

Then there is a graphic listing future technology involving “Particle based formulation for delivery”:

dsRNA (Shrimp viruses)
asRNA (Other shrimp pathogens)
mRNA (Fish vaccines)
Plasmid DNA (Fish/Shrimp Vaccines)

Continued

Crediting Secondary References

https://thehayride.com/2023/09/garlington-now-theyre-coming-for-the-shrimp/
https://thehayride.com/2023/05/garlington-is-there-mrna-in-your-bacon/
https://www.globalresearch.ca/mrna-vaccines-headed-shrimp/5832466
https://www.lewrockwell.com/2023/05/joseph-mercola/what-safety-studies-have-been-done-on-mrna-swine-vaccines/
https://rwmalonemd.substack.com/p/mrna-vaccines-in-livestock-and-companion
https://tomrenz.substack.com/p/eat-your-vaccines-i-mean-vegtables
https://www.usatoday.com/story/news/factcheck/2023/02/15/fact-check-false-claim-mrna-vaccines-food-supply/11218991002/
https://www.globalresearch.ca/mrna-vaccines-in-farm-animals-pork-beef-shrimp-self-amplifying-mrna-vaccines-for-livestock/5833864
https://www.cbc.ca/news/canada/kitchener-waterloo/university-of-guelph-ontario-veterinary-college-covid-19-1.6901872